Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial.
Mao YangYuhao ZhaoYongsheng LiXuya CuiFatao LiuWenguang WuXu-An WangMaolan LiYun LiuYing-Bin LiuPublished in: BMJ open (2023)
NCT04183712.
Keyphrases
- open label
- study protocol
- clinical trial
- locally advanced
- papillary thyroid
- early stage
- randomized controlled trial
- squamous cell
- phase iii
- tyrosine kinase
- squamous cell carcinoma
- epidermal growth factor receptor
- cross sectional
- radiation therapy
- rectal cancer
- double blind
- advanced non small cell lung cancer
- combination therapy
- lymph node metastasis
- cell free
- replacement therapy